SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
STAMFORD, Conn., Oct. 31, 2016 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced the presentation of two posters at Kidney Week 2016, the American Society of Nephrology's Annual Meeting, which will be held November 15-20, 2016 at McCormick Place in Chicago.
Robert Spencer, Ph.D., Senior Director, Research & Development at Cara, will present the following poster:
Title: “Antipruritic Effect of the Long-Acting Peripheral Kappa Opioid Receptor Agonist CR845: A Novel Approach for the Treatment of Uremic Pruritus in Hemodialysis Patients”
Abstract Number: 3421
Location: Exhibit Hall, McCormick Place, Chicago
Date: Thursday, November 17, 2016
Time: 10:00 a.m. – 12:00 p.m. CT
Additionally, Vandana S. Mathur, M.D., F.A.S.N., President at Mathur Consulting, will present a poster titled “Improvement of Quality of Life in Hemodialysis Patients with Uremic Pruritus as Measured by the Skindex-10 Questionnaire: Effect of a Novel Kappa Opioid Receptor Agonist, CR845” (abstract number 4032) in the Exhibit Hall on November 17 from 10:00 a.m. – 12:00 p.m. CT.
Both posters will be on display November 17 from 9:30 a.m. – 2:30 p.m. CT.
For more information on Kidney Week 2016, visit: https://www.asn-online.org/education/kidneyweek/.
About CR845
CR845 is a peripherally acting kappa opioid receptor agonist currently in development for the treatment of acute and chronic pain and pruritus. In multiple randomized, double-blind, placebo-controlled Phase 2 trials in patients undergoing laparoscopic hysterectomy or bunionectomy procedures, I.V. CR845 treatment resulted in statistically significant reductions in both pain intensity and opioid-related side effects. In a human abuse liability trial, I.V. CR845 demonstrated statistically significant reductions in “drug liking,” “feeling high,” “overall liking,” and “take drug again” scores in comparison to I.V. pentazocine, a Schedule IV analgesic.
An oral formulation of CR845 is currently being evaluated in a Phase 2b study in osteoarthritis patients and was shown in a Phase 2a study to be well tolerated with twice a day dosing for two weeks, with evidence of decreasing pain scores during that time period.
In approximately 1,150 subjects dosed to date, CR845 was found to be well tolerated, without incurring the dysphoric and psychotomimetic side effects that have been reported with centrally acting (CNS-active) kappa opioid receptor agonists.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates that target the body's peripheral nervous system and have demonstrated initial efficacy in patients with moderate-to-severe pain without inducing many of the undesirable side effects typically associated with currently available pain therapeutics.
INVESTOR CONTACT: Steve Silver Stern Investor Relations 212-362-1200 [email protected] MEDIA CONTACT: Annie Starr 6 Degrees 973-415-8838 [email protected]
